65.00
+0.78%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Unicocell Biomed Co
Its shares trade on Taiwan Stock Exchange under the ticker 6794.TW. It has been listed since 25 December 2020. In the fiscal year to 31 December 2025, it reported revenue of TWD 30.1m and a net loss of TWD 114.8m. At that date it held total assets of TWD 946.0m and shareholders' equity of TWD 865.4m.
UnicoCell Biomed Co., Ltd. is a biomedical company that mainly focuses on the development of stem cell therapeutic product, cell therapy technology, and regenerative medicine applications. The company is headquartered in Taipei City, Taipei. The company went IPO on 2020-12-25. The main products include stem cell secretin and cell testing services. The firm's current development projects are divided into human adipose-derived mesenchymal stem cells, autologous adipose stem cell transplantation and cell preparation application products. The clinical trials of human adipose-derived mesenchymal stem cells include the ELIXCYTE-CT21 clinical trial project and the ELIXCYTE-CT31 clinical trial project. Autologous adipose stem cell transplantation is used for large-area burns and difficult wound healing. The cell preparation application products include stem cell secretin, which is a conditioned medium derived from cultured stem cells, used to improve skin dullness and fine lines.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 25 Dec 2020
- Website
- unicocell.com ↗
Leadership
Pay as last reported
- Ms. Yiwen CaiChairman of the Board, Chief Strategy Officer, since 2018
- Ms. Yipei HongGeneral Manager
- Mengting LiuHead of Accounting & Finance, Corporate Governance Officer
- Mr. Chia-Fung ChangDirector
- Ms. Meihua LingDirector
- Ms. Xiumei XieDirector
- Ms. Yizhen XieDirector
- Mr. Chengren ChenIndependent Director
- Ms. Sulan LinIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Unicocell Biomed's stem cell secretin product improves skin dullness and fine lines effectively.
- The ELIXCYTE-CT21 clinical trial project advances stem cell therapeutic development.
- Autologous adipose stem cell transplantation treats large-area burns and difficult wounds.
Weaknesses
- The company's IPO was on 25 December 2020, a relatively recent listing.
- Limited product range focuses solely on stem cell applications.
- Taipei City headquarters may limit global market access.
Opportunities
- Expanding stem cell secretin use in cosmetic applications across Asia.
- Growing demand for regenerative medicine in the Health Care sector.
- Potential for international clinical trials in the Biotechnology industry.
Threats
- Competition from established Biotechnology firms in the Health Care sector.
- Regulatory challenges for stem cell therapies in multiple countries.
- Dependence on clinical trial success for product approval.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.